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Summary
What is already known about this topic?
The human papillomavirus (HPV) vaccine is an effective but underused
method for preventing multiple cancers, particularly cervical cancer. Al-
though many evidence-based interventions exist for increasing HPV vac-
cine uptake, little is known about the implementation of these interven-
tions.
What is added by this report?
Our study identifies facilitators and barriers to delivery of evidence-based
interventions for HPV vaccination in federally qualified health centers us-
ing an implementation science framework.
What are the implications for public health practice?
Training, capacity building, use of electronic health systems, and imple-
mentation tools are important factors for successful implementation of
evidence-based interventions for HPV vaccination.
Abstract
Purpose and Objectives
The human papillomavirus (HPV) vaccine is an effective but un-
derused method for preventing multiple cancers, particularly cer-
vical cancer. Although interventions have successfully targeted
barriers to HPV vaccine uptake in various clinical settings, few
studies have explored their implementation. Our study examines
the delivery of the HPV VACs (Vaccinate Adolescents Against
Cancer) Program and elicits information on barriers and facilitat-
ors to implementation.
Intervention Approach
The VACs Program pilot was a multilevel, evidence-based inter-
vention conducted by the American Cancer Society in 30 feder-
ally qualified health centers (FQHCs) in the United States.
Evaluation Methods
We conducted in-depth interviews (N = 32) by telephone with rep-
resentatives  of  9  FQHC partners.  We structured the interview
guides on Consolidated Framework for Implementation Research
(CFIR) domains. We asked about project start-up activities, imple-
mentation strategy selection, policy- and practice-level changes,
staffing structure, challenges, and key factors leading to project
success. At least 2 researchers coded each interview transcript ver-
batim.
Results
Participants most frequently identified the electronic health record
system, training and education, concrete tools and resources, and
provider champions as facilitators to implementing HPV VACs.
Limited staff resources, challenges of electronic health records, is-
sues with state immunization registries, patient misinformation
about  vaccines and vaccine stigma,  cultural/language barriers,
competing  priorities,  levels  of  funding,  staff  buy-in,  training
needs, and low health literacy were identified as barriers.
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Implications for Public Health
Providing appropriate training for FQHC staff members and pro-
viders along with technical assistance and facilitation tools were
critical for increasing provider confidence in recommending HPV
vaccine. Addressing capacity-building and implementation barri-
ers in FQHCs can increase effective implementation of evidence-
based interventions to increase HPV vaccination uptake and re-
duce the burden of future cancers.
Introduction
About 4 of 5 people in the United States will get human papillo-
mavirus (HPV) at some point in their lives (1). Each year, an es-
timated 32,500 Americans receive a diagnosis of cancer associ-
ated with HPV (2). Through HPV vaccination, about 29,000 cases
of cancer could be prevented each year in the United States (2).
Despite this opportunity, only 60% of adolescents in the United
States initiated HPV vaccination in 2016, and only 43.4% of those
aged 13 to 17 were up to date with the HPV series (49.5% for
girls; 37.5% for boys), leaving many children exposed to future
cancer risk (3,4). The Centers for Disease Control and Prevention
estimates that if the HPV vaccine were routinely given with other
recommended vaccines, HPV vaccination rates could exceed 90%
(5).
Many barriers to HPV vaccination exist, including providers’ abil-
ity to give a confident recommendation to vaccinate, parental hes-
itancy, and missed opportunities to vaccinate (6). A provider re-
commendation is one of the strongest predictors of HPV vaccina-
tion; parents who receive a strong recommendation are more likely
to vaccinate their adolescent than those who do not (7–9). HPV
vaccination is  also influenced by practice factors,  such as  ad-
equate health information systems that include provider or patient
prompts for vaccine administration (10). Interventions to address
both provider capacity to deliver an effective recommendation to
parents and system challenges have increased HPV vaccination
rates in various clinical settings (11). However, few explorations
of the delivery of HPV vaccine interventions have been studied
qualitatively. The Consolidated Framework for Implementation
Research (CFIR) is a theoretical model often used in implementa-
tion research to study factors that affect implementation through
quantitative or qualitative methods (12). Only 2 qualitative stud-
ies have explored barriers (eg, lack of appointment reminders, lan-
guage) and facilitators (eg, publicity about the vaccine) related to
HPV  vaccination  in  health  centers  across  the  CFIR  domains
(13,14).  More research is  needed to explore the prevalence of
these barriers and facilitators across health care settings and popu-
lations served.
 
Purpose and Objectives
The purpose of this study was to examine the delivery of the HPV
VACs (Vaccinate Adolescents against Cancers) Program and to
elicit information on barriers and facilitators to implementation re-
lated to CFIR domains and constructs. The VACs pilot program
was a multilevel intervention conducted by the American Cancer
Society (ACS) in 30 federally qualified health centers (FQHCs) in
the United States. FQHCs are community-based health care cen-
ters that receive funds from the Health Research Services Admin-
istration’s Health Center Program to provide primary care ser-
vices in medically underserved areas. The VACs Program’s goal
was to increase HPV vaccination rates among adolescents aged 11
or  12  nationwide.  VACs includes  work  on  many levels,  from
state-level coalition building to clinical interventions. The inter-
vention (hereinafter, “the project”) was a pilot project in 2015 to
implement evidence-based quality improvement interventions with
FQHC partners nationwide to increase HPV vaccination rates. The
project  was implemented by ACS Primary Care Systems staff
members who collaborated with FQHC systems. These staff mem-
bers help FQHCs and other primary care system partners imple-
ment cancer prevention and early detection efforts. To prepare for
the project, ACS Primary Care Systems staff members received 16
hours of intensive training provided by doctoral-level members of
our research team with expertise in quality improvement coaching,
HPV vaccination science, and evidence-based interventions to in-
crease HPV vaccination rates in the primary care setting. During
the pilot,  partner FQHCs increased their  HPV series initiation
rates by an average 15.4% (15).
Intervention Approach
Thirty FQHC systems implemented the project in 130 clinical or
school-based sites. ACS randomly placed the systems into 3 inter-
vention groups,  with 10 systems in each group:  one group re-
ceived a $90,000 2-year grant, another group received a $10,000
12-month grant, and another group received training and technical
assistance  but  no  funding.  Intervention  requirements  differed
somewhat between groups, allowing us to explore the effect of
varying funding levels, time frames, and requirements. Details on
the selection process are available elsewhere (15).
The intervention included both system-focused components aimed
at removing systemic barriers to vaccination and provider-focused
components (eg, training, provider prompts, standing orders, as-
sessment and feedback) aimed at improving the quality of pro-
viders’ recommendations for the HPV vaccine. Some FQHC sys-
tems also implemented patient-focused reminder and recall com-
ponents. In all 3 groups, FQHC systems worked with ACS part-
ners to educate their staff on HPV vaccination and train providers
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to make an effective recommendation for the HPV vaccine. All 3
groups were also required to complete a capacity assessment tool,
calculate baseline HPV vaccination rates, and modify their elec-
tronic health record (EHR) systems to support the project (eg, vac-
cination reports, provider prompts). Beyond these core strategies,
we encouraged the FQHC systems and ACS Primary Care staff
members to choose additional strategies for evidence-based inter-
ventions, such as provider assessment and feedback, standing or-
ders for HPV vaccination, provider prompts, and patient remind-
ers, on the basis of needs identified during the capacity-building
phase. The $90,000 group was required to use at least one addi-
tional implementation strategy, but many FQHCs in the other in-
tervention groups did so as well.
Evaluation Methods
We conducted in-depth interviews by telephone of a sample of
FQHC staff members and ACS Primary Care Systems staff mem-
bers. Nine FQHC partners participated in the interviews: 5 sys-
tems funded at $90,000, 2 systems funded at $10,000, and 2 un-
funded systems. We selected FQHCs on the basis of several criter-
ia, including not having participated in a previous technical assist-
ance site visit, degree of success in improving rates of HPV vac-
cination uptake, geographic location, urbanicity, and population
served. We purposely chose 5 FQHCs that received $90,000. The
evaluation team contacted ACS Primary Care Systems members
who were partnering with the selected FQHCs, and these staff
members contacted the FQHC to request an interview and ask for
a list of participating staff members who would be appropriate for
an interview. One FQHC declined to participate, so we selected
another FQHC from the same funding group.
The ACS evaluation team, in partnership with the HPV VACs
project team, developed the interview guides.  Topics included
project  start-up  activities,  implementation  strategy  selection,
policy-level and practice-level changes, staffing structure, project
challenges, and key factors leading to project success. Interview
guides were structured on CFIR domains: intervention character-
istics (key attributes of the intervention), outer setting (contexts
outside of the organization), inner setting (structural and cultural
processes within the organization), characteristics of individuals
(characteristics of the individuals receiving and interacting with
the intervention), and implementation process (how and by whom
an intervention is delivered) and their associated constructs (14).
Questions  were  similar  across  FQHCs,  although  we  tailored
guides to each respondent type (eg, project champion, nurse).
We conducted 32 interviews from May to August 2016; the num-
ber of interviewees per FQHC ranged from 2 to 5. The unit of ana-
lysis was the FQHC. Respondents included project champions,
nurse coordinators or nurse practitioners overseeing project imple-
mentation, quality improvement directors, chief medical officers,
and nurses and medical assistants responsible for administering
vaccinations. We also conducted interviews with ACS Primary
Care Systems staff members working with the 9 FQHCs on the
project.
All interviews were digitally recorded and transcribed verbatim.
On the basis of the interview guide and CFIR constructs, we de-
veloped a provisional  codebook of  codes and definitions.  The
Emory research team revised the codebook after reviewing the
first few transcripts. Once the Emory research team reached con-
sensus on codes and definitions, 7 team members coded the inter-
view transcripts independently. At least 2 team members coded
each transcript, and the team resolved discrepancies. We applied a
quasi-deductive approach to data analysis, which emphasized both
a deductive and an inductive approach (16). In the first stage, we
coded transcripts deductively on the basis of CFIR constructs and
definitions, and researchers coded strictly on the basis of the CFIR
domains without making inferences from the data. In the second
stage, we applied an inductive approach to the first level of codes,
seeking to identify subthemes within CFIR domains. We created
matrices  of  key  themes,  and  then  we  assessed  the  number  of
FQHCs identifying each barrier and facilitator. Only barriers and
facilitators that were described by 2 or more FQHCs were incor-
porated into this study. Additionally, we applied a rating system
with 2 dimensions: magnitude and valence. “Magnitude” refers to
the extent to which the constructs were discussed; we counted the
number of times each construct was discussed and tabulated data
according to whether 1 respondent noted the construct  or 2 or
more respondents did so. We further organized the data by fund-
ing level (grant of $90,000, grant of $10,000, and technical assist-
ance only). “Valence” refers to the construct’s influence on imple-
mentation of the program. We considered valence to be positive
(facilitated implementation of the intervention), negative (hindered
the implementation), or mixed. We tabulated these data for each
construct and further organized by funding level.
Results
The sample FQHCs represented a mix of urban, rural, and suburb-
an settings; 2 systems had multiple locations in a mix of settings.
The number of clinics in each FQHC system ranged from 5 to 22
(Table 1). The number of patients in the eligible age range for
HPV vaccination ranged from 661 to 2,777. Common implement-
ation strategies were training (5 of 9 FQHCs trained at least 75%
of their staff members) and provider prompts (5 of 9 FQHCs used
provider prompts).
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Facilitators to implementing HPV VACs
The strongest facilitators, occurring in 4 or more of the FQHCs in-
terviewed, centered on the CFIR domain of intervention process.
They were usefulness of EHR systems, ACS staff support, train-
ings, concrete tools and resources, and provider champions. Ex-
amples of themes by CFIR domain and a representative quote fol-
low.
Intervention process
EHR system (7 FQHCs). The EHR system was a central focus of
the initiative, not only for tracking vaccinations but also for re-
minding providers. Seven of 9 FQHCs integrated reminders for
HPV vaccination into their already established EHR system. A
nurse practitioner stated, “We actually already had a prompt built
into the EMRs [electronic medical records], so it wasn’t a whole
lot of work on our end.”
ACS staff support (7 FQHCs). Another key facilitator commonly
mentioned  was  the  training,  technical  assistance,  and  support
offered by ACS staff. A research coordinator commented, “We
have a  really great  ACS staff  member,  so everything is  going
good.”
Provider champions (5 FQHCs). Engaging with influential people
who actively support an intervention can be an important boost to
implementation. Designating a provider champion who helped en-
courage program objectives reinforced HPV vaccination as a pri-
ority. In addition to affirming the importance of HPV vaccination,
this symbolic appointment helped ensure that education and mes-
saging  spread  consistently  among  clinic  personnel.  An  ACS
Primary  Care  Systems  staff  member  shared  how  a  physician
champion was instrumental to implementation in her clinic:
It was Dr. [name] who said we’re going to take this and everybody
got on board. . . . [H]e’s been a champion from day one. And that
makes things easier. If I compare my other two [projects], the other
educational grant that I have, I think the key here is that he is a
champion and he gets it, and he sees the value and the import-
ance of it. So for me, that has been the key here.
Training and education (5 FQHCs). Many FQHCs reported that
training from ACS and/or pharmaceutical representatives was es-
sential in ensuring that all team members had the knowledge ne-
cessary to implement the project. In particular, this training was
important for medical assistants — frontline workers assigned to
educate patients about the HPV vaccine who, before the training,
often did not have the knowledge necessary to effectively com-
plete this task. Providers expressed greater confidence in the vac-
cine and their ability to talk with patients about vaccination after
the training. A clinical coordinator of pediatrics said the following:
I thought the education was probably one of the most important
pieces. I  didn’t realize how much some of the staff really didn’t
know about it. . . . So I think it was eye opening, especially to some
of the medical assistant staff that were kind of on the fence. Per-
sonally on the fence with their own children and hard for them to
probably make, I would think, a strong recommendation if they are
on the fence themselves. So I  think that was a really important
piece.
Tools and resources (5 FQHCs). Along with educating providers,
having accessible tools, such as posters highlighting HPV vaccina-
tion,  was considered a critical  tool  for successfully increasing
HPV vaccination. FQHCs described how having available patient
resources  helped  initiate  conversation,  and  at  times  these  re-
sources would prompt parents to begin the discussion. A nurse
practitioner described, “I think the posters have been a nice addi-
tion. . . . I think that was helpful in starting a conversation, by the
time you walk in the room it’s already — the parent’s already read
about it and decided.”
Written protocols and processes (3 FQHCs). Having formal pro-
cesses in place helped with implementation of the VACs program.
One health provider remarked, “I think having a strategic plan re-
garding everyone being on the same plate and doing things the
same  way  in  each  center  because  if  each  center  was  doing
something different, it would be crazy.”
Inner setting
The second group of major facilitators related to the inner setting.
They represented critical areas such as leadership support, clinical
staff support, communications, and teamwork.
Leadership support (4 FQHCs). In addition to staff support and
teamwork, supportive leadership was important, especially when
there were competing demands. Four FQHCs indicated the import-
ance of leadership support for prioritizing the project when other
demands might take have taken precedence in daily operations.
One quality improvement director stated the following:
Oh, the executive team is very supportive. I report straight to the
CEO [chief executive officer] and the chief operations officer. We
couldn’t have done it without them because again, I mean working
with operations and the CMO [chief medical officer] you have to
work as a team in order to roll out a QI [quality improvement] initiat-
ive that you may want to. If you don’t have support then projects
are not successful.
Clinical staff support (4 FQHCs). Four FQHCs acknowledged the
importance of active involvement of clinic staff in communicating
and promoting awareness among their peer network. For some
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FQHCs this was a specific “peer coordination team” and for oth-
ers, a particular nurse or physician took on these roles.
Communication (4 FQHCs). Four FQHCs mentioned the import-
ance of effective verbal communication among staff members as a
facilitator. Those who described communication as a facilitator ap-
preciated the complexity of communicating with a large group of
individuals  who  each  had  competing  demands  and  priorities.
These FQHCs described identifying effective methods of commu-
nication, which could possibly adapt over time given changing
needs, as particularly important given the network of providers
spread over multiple clinics.
Teamwork (3 FQHCs). A pediatrician stated, “I think it’s team-
work. I mean, just someone in charge, tracking the monthly things.
That’s the key factor that will help buy success in this project.”
Other CFIR domains
Some CFIR domains comprised themes that were mentioned as fa-
cilitators by only 2 or 3 FQHCs (Table 2). Related to outer setting,
the presence of patient buy-in and creation of partnerships for pro-
motion of the vaccine and vaccination (eg, pharmaceutical com-
panies, schools) emerged as themes. Noted as contributing to pro-
gram implementation was the fact that the VACs program was
compatible and could be integrated easily because some FQHCs
had good systems developed for other health projects, and that
staff members had knowledge about HPV and the vaccine.
Barriers to implementing HPV VACs
All FQHCs reported both barriers and facilitators (Table 2). Sever-
al  barriers were in all  CFIR domains;  however,  the frequently
mentioned barriers were in intervention process, inner setting, and
outer settings. Descriptions of the most common barriers by CFIR
domain and a representative quote follow.
Intervention process
For the intervention process, 2 FQHCs mentioned difficulties in
acquiring the HPV vaccine, and all 9 FQHCs reported difficulties
in  executing  the  VACs  program.  These  difficulties  revolved
around EHRs, staff time, and reaching patients.
EHR issues (8 FQHCs). Although EHRs facilitated HPV vaccina-
tion through features  such as  provider  reminders,  study parti-
cipants also identified barriers in using their EHR system and bar-
riers in communication between their own EHR systems and oth-
er systems. Eight FQHCs mentioned the EHR system as a barrier
to  full  and  effective  program implementation.  Challenges  in-
cluded obtaining information on baseline HPV vaccination com-
pletion rates for all 3 doses and switching EHR systems during the
project. One director of quality and risk management stated he was
not able to use the EHR system to capture data in the project be-
cause “we went to a new EHR and the data in the prior EHR that
we had did not move over to the new system.”
Staff resources, including time (8 FQHCs). Staff resources were
cited as a major barrier to implementing the HPV vaccination pro-
gram in 8 FQHCs. Resources, for the purpose of this study, were
defined as references to money, training,  education,  materials,
physical space, and time. Most staff resources barriers revolved
around the idea that taking providers out of the clinic for trainings
slowed down productivity and the clinic’s ability to provide care
to their patients. Numerous clinics also reported that taking time
for training and other intervention processes would cost the clinic
in terms of lost revenue. A family nurse practitioner stated, “Any
time you have to pull medical assistants or receptionists, front end
staff out of practice, you’re minimizing or making a challenge for
people to get in for care, which is the opposite of what we’re try-
ing to do.”
Inner setting
Barriers in the inner setting reflected relative priority of the VACs
program, readiness for implementation through staff buy-in, avail-
able resources, communications, and need for training.
Competing priorities (7 FQHCs). Seven FQHCs reported compet-
ing priorities that negatively affected project implementation. In
particular, fitting the project into the existing workflow, given the
demands of acute walk-in patients who required immediate assist-
ance, was a challenge. One registered nurse panel manager stated,
“Keeping in the forefront with other duties that the medical assist-
ants and providers have; they’re constantly being inundated with
things that have to be taken care of in the system for documenting
and so on.”
Staff buy-in (5 FQHCs). Although a system was in place whereby
clinical staff communicated with their peers to get buy-in, this
communication  did  not  happen  for  some staff  members.  Five
FQHCs  stated  that  not  all  staff  members  were  committed  to
project implementation. Front desk staff members and providers
showed occasional resistance to the program because of the major
changes in protocol the project required, resulting in slower imple-
mentation of the project. One director of quality and risk manage-
ment stated, “Staff are not assisting me in scheduling them for
their second and third HPV, so that has to be a learning curve and
education for the staff, and we are doing much better to get their
commitment to that now.”
Training needs (5 FQHCs). Five FQHCs reported barriers to im-
plementation that focused on training needs. Formal education was
a major piece of this intervention, and although formal education
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facilitated implementation, some FQHCs also had ideas on how to
improve uptake of key information. Some FQHCs faced problems
disseminating information to clinical and nonclinical staff using
terminology and examples that were appropriate across their roles.
One ACS primary care manager stated, “We’re trying to engage
their scheduling staff, their front desk staff who aren’t clinical,
don’t have a clinical background to understand the message and to
help engage clients. A lot of the training . . . [is] more clinically
focused.”
Communication (3 FQHCs). Communication challenges were re-
ported; an ACS staff member stated, “With the HPV project, . . .
we had these HPV champions, the provider champion, and these
MAs  [medical  assistants]  per  clinic  site  to  help  facilitate  the
projects. It’s a lot harder to get them together to meet as a group to
talk about how the project is coming along.”
Outer setting
Barriers  in  the  outer  setting  domain  reflected  patient-related
factors, such as misinformation, language barriers, and low levels
of literacy. In addition, linkage to the state immunization regis-
tries was often noted as challenging.
Patient misinformation and vaccine stigma (8 FQHCs). Providers
reported difficulties recommending the HPV vaccine to patients
when vaccine stigma and patient/parent misinformation surround-
ing HPV and its vaccine existed. Many parents had either general
antivaccine sentiments — whereby they refused all optional vac-
cines — or they had negative opinions of the HPV vaccine spe-
cifically.  Many parents  believed the  vaccine  promoted sexual
activity in their children or they thought children only needed the
vaccine if they were sexually active. One medical assistant trainer
stated, “They feel that, oh my child isn’t sexually active, so I don’t
need that.”
Cultural or language barriers (5 FQHCs). Cultural and language
issues were mentioned as a barrier to implementation in 5 FQHCs.
Frequently, FQHCs required more skills and materials to accom-
modate their non–English-speaking patients than their English-
speaking patients. One director of quality and clinical practice
management stated, “The only problem that we do have is that we
don’t have anything in Creole. So that makes it complicated.”
Low health literacy (4 FQHCs). Four FQHCs said that increased
resources were necessary for educating patients with low health
literacy. Many patients with low health literacy had very little ex-
perience with primary care, and thus were not accustomed to re-
ceiving preventive care. A chief medical officer stated, “Prior to
the Affordable Care Act a lot of these people had no insurance. . . .
[T]here is also a cultural deficit of health literacy just because
there’s never been any access to health care.”
State registry issues  (6 FQHCs).  Six FQHCs faced issues with
their state immunization registry. Most states have an online im-
munization information system where providers are required to re-
port all immunizations administered at their FQHC. Ideally, an
EHR system communicates with the state registry to prevent the
need for separate data entry into both systems and reconciliation
between the 2 systems. Many FQHCs did not have bidirectional
communication between their EHR system and state immuniza-
tion registry, resulting in more work for providers and staff mem-
bers to ensure both systems are accurate and up-to-date. An ACS
representative stated, “The immunization, for our state, it’s not bi-
directional  with the immunization registry.  So it  is  incumbent
upon the FQHC to keep that updated.”
Level of ACS funding/cost of program (5 FQHCs). Five FQHCs
mentioned that the cost of the program and the level of funding
from ACS were incompatible, resulting in concerns that the fund-
ing provided was not adequate for the effort required. One of these
FQHCs received $90,000, 2 received $10,000, and 2 received only
technical assistance. One nurse practitioner stated, “I think we
ended up with a $10,000 reward, which doesn’t really cover the
costs as you can imagine for all the work that we do.”
A smaller set of FQHCs mentioned patient reach, communication
between provider and caregivers, insurance provider coverage is-
sues, incomplete program information from ACS, and barriers that
centered on vaccine acquisition (Table 2).
Distribution of themes within CFIR domains
When we charted how barriers and facilitators were distributed
across CFIR domains and constructs, we found that the FQHCs re-
ported barriers or facilitators in 2 of 8 possible constructs for inter-
vention characteristics, 3 of 4 possible constructs for outer setting,
3 of 5 possible constructs for inner setting, 6 of 8 for process, and
1 of 5 for individual characteristics (Figure). For example, facilit-
ators for outer setting constructs relate to patient needs and re-
sources (family buy-in) and cosmopolitanism (ie, collaborating
with ACS in incorporating evidence-based interventions into their
practices). Implementation facilitators were concentrated in the in-
ner setting and process domains, whereas barriers were distrib-
uted throughout the range of domains, except for Individual Char-
acteristics. We found no domains in which all 9 FQHCs reported
facilitators to implementation; 9 reported barriers across 2 do-
mains: patient needs and resources (outer setting) and readiness
for implementation (inner setting). For example, many barriers
were related to the construct of patient needs and resources, in-
cluding misinformation or hesitancy among patients and care-
givers, language barriers of families served, and external policies.
CFIR constructs generally were representative across sites; most
were mentioned across at least 2 sites (all but 2 themes) (Tables 3
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and 4). The construct named most often (by 7 FQHCs) as a facilit-
ator was “executing,” in the process domain. Some factors had
both positive and negative effects on implementation, particularly
in the domains of intervention process, inner setting, and outer set-
ting (Table 5).
Figure. Major themes of barriers and facilitators to implementing the HPV
VACs (Vaccinate Adolescents Against Cancers) Program across domains of the
Consolidated Framework for Implementation Research (CFIR), May–August
2016. This figure does not show all possible constructs, because the federally
qualified health centers participating in the study did not report barriers or
facilitators for every construct.
Implications for Public Health
Our study identified CFIR-related barriers and facilitators to im-
plementing the HPV VACs Program. The most salient facilitators
aligned with the intervention process and inner setting, a finding
supported by other implementation science research, indicating
that organizations should consider the implementation process and
organizational context when adopting evidence-based interven-
tions (17). A recent qualitative study of a pediatric consortium
found many facilitators related to CFIR domains of inner setting,
intervention staff,  and intervention process (14).  Our findings
show the importance of early planning, engaging staff members
and champions, and planning for implementation during the inter-
vention process. The primary facilitators were the use of EHRs
and training (intervention process) and education for providers (in-
ner setting). The EHR system is critical to various parts of HPV
vaccination services, including documenting vaccination, tracking
reminders for the subsequent dose, and generating reports on ad-
olescents who are eligible and those who are vaccinated and re-
ports on missed opportunities (18). Future implementation should
also consider the need to provide adequate support to health sys-
tems over time about the importance and use of their EHR system
to prompt clinic staff to offer a vaccination, document vaccina-
tions, follow up on series completion, and track their health sys-
tem’s progress on vaccination. Consultation and education from a
technical assistance provider, a strategy used in several HPV inter-
ventions (19–21), was identified as an important component of
successful implementation in our study. Training and skill-build-
ing activities are needed to promote provider self-efficacy to coun-
sel parents about vaccination. Building the capacity for alerts or
reminders for parents and facilitating communication about vac-
cine series completion with state immunization registries also are
foundational in implementing HPV promotion programs in health
centers.
Our study also found that unfunded FQHCs used similar imple-
mentation strategies (eg, training, technical assistance, facilitation)
and had similar outcomes to funded FQHCs (22), suggesting that
ACS staff support or committed FQHC staff members, rather than
funding, was the key to project success. These concerted efforts to
facilitate CFIR factors related to the execution of the program (in-
tervention process)  were critical  elements.  Other  research has
found parallel results and reported a relationship between training
of program implementers and tools  and adoption of evidence-
based practices (17,22). Furthermore, a review of interventions to
improve physician learning and practice found that educational
materials, outreach visits, opinion leaders, and reminders were
moderately effective strategies (23). Studies have demonstrated
that use of EHR alerts for health care providers alone or in com-
bination with other strategies improves HPV vaccine completion
(21,24). Not surprisingly, a strong theme in our study was the use
of EHRs to alert providers to recommend vaccination to unvaccin-
ated teenagers. A quantitative study also found that EHRs were
both a facilitator and a barrier, crucial to calculating vaccination
rates and reminding providers and patients but also presenting
challenges in data quality and reporting (13).
In contrast, barriers for implementing evidence-based interven-
tions (eg, staff resources) were concentrated in the domains of im-
plementation process, inner setting, and outer setting. Our finding
of a critical mass of barriers (ie, high magnitude) in the outer set-
ting demonstrates the importance of understanding patient issues
about the vaccine and social and external influences that affect
community awareness and vaccine delivery. The use of CFIR to
elucidate themes that have a positive effect on implementation (ie,
positive valence) is important to successful implementation of
evidence-based interventions and inform potential solutions to ad-
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dress barriers. Some factors had positive and negative effects on
implementation, and it is important to have qualitative methods for
implementation  studies  to  elicit  information  on  these  salient
factors.
Perceived barriers are important to address because they can lead
to missed opportunities to vaccinate (20,25). FQHCs reported in-
ner setting constructs (staff resources/time and competing priorit-
ies) were major limitations to implementing HPV vaccine pro-
grams. Likewise, outer setting variables were challenges to imple-
mentation. Other key barriers were the ability to communicate bid-
irectionally with the state immunization registry and patient needs
related to language and literacy. These patient-related factors (par-
ental knowledge and antivaccine sentiment) are frequently repor-
ted as critical barriers (6,26). Subsequently, health care providers
reported vaccine safety concerns among parents and not having
adequate time to discuss these concerns during visits (18,27,28).
However, providers’ recommendations of the vaccine and higher-
quality recommendations are associated with vaccine initiation
and series completion (29). Potential tools are materials for pro-
viders’ office or parental education (eg, fact sheets) through the
Centers for Disease Control and Prevention (2) and the American
Academy of Pediatrics HPV Champion Toolkit (30), which assist
with practice changes to increase vaccination rates. Finally, anoth-
er strategy is to assess parental concerns through surveys (31).
In a recent systematic review of interventions designed to increase
HPV vaccination, only 11 of 34 interventions focused on provider-
or  system-based interventions;  researchers called for  more re-
search for interventions to promote implementation of effective
strategies (32). Others have called for more provider/physician in-
terventions to promote HPV vaccine uptake (10). Future research
should evaluate multiple components of interventions, such as this
initiative, on increasing the initiation and completion of HPV vac-
cine series among adolescents and young adults. The FQHCs in
our study used various implementation strategies. Future evalu-
ations can assess which implementation strategies or combination
of strategies could increase HPV vaccination rates (33,34). Addi-
tional implementation science studies could examine how CFIR is
operationalized in practice and validate our themes mapped as
CFIR constructs around barriers and facilitators. Use of an imple-
mentation theoretical framework such as CFIR contributes to a
broader understanding of contextual barriers and facilitators. Fu-
ture implementation study can use theory to inform a deeper un-
derstanding of factors that affect implementation (35,36). Addi-
tional exploration of the use of CFIR constructs in implementa-
tion research has been recommended, particularly on how con-
structs may affect implementation and outcomes (37).
Our study reports facilitators and barriers identified by 9 FQHCs
that received varying levels of funding and may be different from
other FQHCs or health centers. The study evaluated a 3-shot vac-
cine regimen; however, recommendations have since changed to 2
scheduled doses 6 months apart (38). Despite this change, our res-
ults remain applicable because of the need for an initial vaccina-
tion and a follow-up.
Our study provides important insights into barriers and facilitators
experienced by clinics stratified by CFIR domains and providers
when promoting HPV vaccination in community settings. Themes
of capacity building such as training and technical assistance, pres-
ence of supports and organizational champions, and key processes
such as EHR infrastructure for  provider  reminders  are salient.
Chung et al noted the challenges of making practice changes and
the importance of considering practice-specific issues when sup-
porting vaccination efforts (39). Furthermore, training and tools
exist to help bolster the self-efficacy of providers and to counsel
vaccine-uninformed or -hesitant parents. Future implementation
should  also  consider  the  need  to  provide  adequate  support  to
health  systems over  time to  integrate  provider  reminders  into
EHRs and promote provider self-efficacy to counsel parents about
vaccination.  It  is  important  to  understand  which  factors  have
shaped the success or  failure of  implementations of  evidence-
based interventions for HPV vaccination in health centers that
reach low-income populations, such as FQHCs. This information
can optimize future implementations of effective HPV vaccine
strategies in this context and reduce the burden of future cancers.
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Tables
Table 1. Characteristics of FQHCs (N = 9) Participating in Qualitative Interviews in a Study of Facilitators and Barriers to Implementing the HPV VACs (Vaccinate Ad-
olescents Against Cancers) Program, May–August 2016
FQHC Outcome Contextual Factors Implementation Strategies
FQHC
ID No.
State
(No. of
Clinics in
System)
Baseline
HPV
Vaccination
Initiation
Rate, %
Percentage-
Point
Change in
HPV
Vaccination
Initiation
Funding
Level Urbanicity
Target
Patient
Population
in 2015
Strong EHR
Capabilities
75% of
Staff
Trained
Client
Reminders
Provider
Prompts
Standing
Orders
Provider
Assessment
and
Feedback
1 North
Carolina
(10)
72.6 23.4 Technical
assistance
Urban 904
2 Maryland
(5)
46.4 22.2 Technical
assistance
Rural 926 √ √ √
3 California
(5)
73.0 No data $10,000 Rural 661 √
4 Maine
(13)
52.3 4.2 $10,000 Rural 1,666 √ √ √ √ √ √
5 Florida
(6)
64.8 24.9 $90,000 Urban 1,613 √ √ √ √ √
6 South
Carolina
(22)
74.8 −18.7 $90,000 Mixed 2,777 √
7 Alabama
(10)
71.2 12.3 $90,000 Mixed 1,541 √ √ √
8 California
(10)
15.8 45.4 $90,000 Suburban 1,862 √
9 West
Virginia
(13)
11.4 3.9 $90,000 Rural 745 √
Abbreviation: √, FQHC has characteristic; EHR, electronic health record; FQHC, federally qualified health center; HPV, human papillomavirus.
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Table 2. Themes of Less Frequently Mentioneda Facilitators or Barriers, Aligned by Domains of the Consolidated Framework for Implementation Research, in Qualit-
ative Interviews in a Study of Implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program in Federally Qualified Health Centers, May–August
2016
Domain/Theme
No. of FQHCs Noting
Barrier Description of Facilitator or Barrier
Facilitators
Inner setting
Teamwork 3 Although it was important to have a champion to help encourage ongoing support of the project, it
was also critical to have team members who were willing to work together to achieve a common goal
across the hierarchy. These teams typically consisted of both clinical staff (eg, nurses, medical
assistants, physicians) and nonclinicians (eg, quality managers).
Intervention characteristics
Compatibility with other similar
projects
3 The VACs project was integrated more easily into FQHCs that had other ongoing projects with similar
requirements. These FQHCs were able to add requirements, such as reporting success rates and
missed opportunities to clinicians, without the need to establish a new process. This limited the
complexity of integrating new activities into existing processes.
Implementation process
Written protocols and processes 3 In addition to human capital, processes were also important to implementation. FQHCs that
developed a written plan found this process to be helpful for ensuring step-by-step tasks were
completed. Uniformity of procedures, such as when to follow up with patients who are due for
vaccination were also useful, particularly for those who had multiple FQHCs in their FQHC system.
These plans were typically written in advance of the program being implemented, but they were
adaptable, and could be changed to meet shifting requirements.
Previsit planning 3 A key process change discussed in several FQHCs was the identification of patients eligible for HPV
vaccination before appointments. This change was particularly helpful for FQHCs that did not already
have similar programs in place. These FQHCs found the training in methods for identifying potential
HPV vaccine candidates helpful for starting this new process of provider counseling.
FQHC visits 2 FQHC visits by ACS staff were important for “hold[ing] people accountable” to the objectives of the
intervention. Additionally, the in-person interaction helped to solidify relationships between ACS
representatives and clinic staff members.
Characteristics of individuals
Staff knowledge 2 Staff familiarity and comfort level with HPV vaccine were important facilitators. Staff knowledge of
facts of HPV was important in building a general knowledge base for justifying the importance of the
vaccine and the scheduled series. This knowledge also extended to building comfort in discussing the
vaccine with patients through increased levels of confidence in staff members’ ability to answer
patients’ questions.
Outer setting
Families and family buy-in 2 Addressing the wide variety of family needs across different patient populations was critical for
meeting the goals of this project. For example, some patient populations had no firsthand knowledge
of vaccine-preventable illnesses and so relied on their provider’s knowledge. Providers sometimes
stated they had or they would give the vaccine to their own children. Other families had emigrated
from locations where vaccine-preventable diseases were prevalent; these first- and second-
generation immigrants were very amendable to preventive vaccines because of their recent history.
Barriers
Process
Incomplete program information
from ACS
3 Three FQHCs reported receiving incomplete program information from ACS. Without a full
understanding of what was required of them, the FQHCs ran into issues with running reports on short
timelines and being unable to prepare their staff for what was required of them on the project.
Vaccine supply acquisition 2 Two FQHCs mentioned that they had issues ordering the vaccine and keeping the vaccine in stock.
One FQHC recounted the process in which they transitioned from the Gardasil 4 vaccine to the
Gardasil 9 vaccine (Gardasil 4 prevents 4 types of HPV and Gardasil 9 prevents 9 types of HPV).
Abbreviations: ACS, American Cancer Society; FQHC, federally qualified health center; HPV, human papillomavirus.
a The facilitators and barriers described in this table were noted by 2 or 3 FQHCs, whereas the facilitators and barriers described in the text were noted by at least 4
FQHCs.
(continued on next page)
PREVENTING CHRONIC DISEASE VOLUME 16, E85
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY           JULY 2019
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
12       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2019/18_0406.htm
(continued)
Table 2. Themes of Less Frequently Mentioneda Facilitators or Barriers, Aligned by Domains of the Consolidated Framework for Implementation Research, in Qualit-
ative Interviews in a Study of Implementing the HPV VACs (Vaccinate Adolescents Against Cancers) Program in Federally Qualified Health Centers, May–August
2016
Domain/Theme
No. of FQHCs Noting
Barrier Description of Facilitator or Barrier
Another FQHC reported they had increased the number of HPV vaccinations in their FQHC to the
extent that they ran out of the vaccine and had to rush to get more in stock. One director of quality
and clinical practice manager recounted, “The financial piece of how we were acquiring vaccines
created a little bit of difficulty because since we’re getting it through a 340B program which is a
discounted price. And we weren’t dealing directly with the vendor. We weren’t able to initially move
away from Gardasil 4 and get the Gardasil 9. So that was kind of a difficult transition since obviously
we had to finish those doses of Gardasil 4.”
Outer setting
Patient reach 3 Another issue related to patients was reaching the appropriate patient population and difficulty with
having children come to clinic for well-child appointments. At the time of the study, 3 appointments
were required to vaccinate against HPV. FQHCs reported higher success rates with the first
vaccination, because it aligned with other vaccines that are required for school attendance, but the
second and third doses was a problem for this hard-to-reach age group.
Communication between providers
and caregivers
3 The quality of communication among people both within the organization and with parents and
patients has the potential to affect the implementation process. Three FQHCs had problems
coordinating communication among a diverse group of clinician and nonclinicians with various
schedules and responsibilities. Communication with parents and patients was also a challenge,
particularly given the framing of HPV vaccine as a choice rather than a requirement. One director of
quality and risk management stated, “You have to be careful how you present it to the parent as well.
Since it’s not required most parents don’t want their child to have it.”
Insurance provider coverage issues 3 Three FQHCs described problems related to billing insurance companies for HPV vaccination. Even
though the Centers for Disease Control and Prevention recommends vaccination starting at age 9,
some insurance companies will not reimburse for children younger than 11. FQHCs reported that
even if they are committed to this project and want to increase vaccine uptake, outside factors such
as inconsistent insurance reimbursement hinder their progress.
Abbreviations: ACS, American Cancer Society; FQHC, federally qualified health center; HPV, human papillomavirus.
a The facilitators and barriers described in this table were noted by 2 or 3 FQHCs, whereas the facilitators and barriers described in the text were noted by at least 4
FQHCs.
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Table 3. Magnitudea of Facilitators by Constructs of Consolidated Framework for Implementation Research and Level of Funding, Study of Implementing the HPV
VACs (Vaccinate Adolescents Against Cancers) Program, May–August 2016
Facilitator
Received $90,000 Received $10,000
Received Technical
Assistance Only
5 6 7 8 9 3 4 2 1
Intervention characteristics
Compatibility with other similar projects ● ●
Intervention staff
Staff knowledge ● ●
Intervention process
Trainings and education ● ● ● ■ ■
Tools and resources ● ● ● ● ●
Written protocols and processes ● ● ●
ACS staff support ■ ■ ■ ● ● ● ●
EHR system ■ ● ■ ■ ● ■ ●
Quality improvement team ■
Previsit planning ● ● ●
Site visits ● ●
Provider champions ● ● ● ● ●
Inner setting
Leadership support ● ● ● ●
Clinic staff support ● ● ■ ■ ●
Communication ■ ● ● ●
Teamwork ● ● ●
Outer setting
Patient needs: families/family buy-in ● ●
Cosmopolitanism: other partnerships (pharmaceutical
companies/schools)
● ■
Abbreviations: ●, 1 Participant noted facilitator; ■, ≥2 Participants noted facilitator; ACS, American Cancer Society; EHR, electronic health record; FQHC, federally
qualified health center; HPV, human papillomavirus.
a “Magnitude” refers to the extent to which the constructs were discussed. Numbers in column headings refer to the FQHC identification number. Thirty FQHC sys-
tems implemented the HPV VACs project. The systems were randomly placed into 3 intervention groups, with 10 systems in each group: one group received a
$90,000 2-year grant, another group received a $10,000 12-month grant, and another group received training and technical assistance but no funding. Nine
FQHCs were selected to participate in qualitative interviews.
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Table 4. Magnitudea of Barriers by Constructs of Consolidated Framework for Implementation Research and Level of Funding, Study of Implementing the HPV VACs
(Vaccinate Adolescents Against Cancers) Program, May–August 2016
Barrier
Received $90,000 Received $10,000
Received Technical Assistance
Only
5 6 7 8 9 3 4 2 1
Intervention characteristics
Incomplete program info from ACS ● ■ ●
Intervention staff
Inconsistent implementation between
providers
● ●
Intervention process
Vaccine acquisition ● ●
EHR issues ● ● ■ ● ■ ● ● ■
Staff resources and time ■ ■ ■ ● ■ ■ ■ ■
Patient reach ● ● ●
Inner setting
Program incompatibility ● ● ● ●
Communication ● ● ■
Staff buy-in ● ● ● ● ■
Competing priorities ● ● ● ● ● ● ■
Training needs ● ● ■ ● ■
Level of ACS funding/cost of program ■ ● ● ● ●
Outer setting
Low health literacy ● ● ● ●
Immigrant population ● ●
Cultural barriers/language barriers ■ ● ● ● ●
Time restrictions for patients ■
Patient misinformation/ vaccine stigma ■ ● ■ ● ● ■ ● ●
Insurance provider coverage issues ● ■ ●
State registry issues ■ ■ ● ● ● ■
Abbreviations: ●, 1 FQHC noted barrier; ■, ≥2 FQHCs noted barrier; ACS, American Cancer Society; EHR, electronic health record; FQHC, federally qualified health
center; HPV, human papillomavirus.
a “Magnitude” refers to the extent to which the constructs were discussed. Numbers in column headings refer to the FQHC identification number. Thirty FQHC sys-
tems implemented the HPV VACs project. The systems were randomly placed into 3 intervention groups, with 10 systems in each group: one group received a
$90,000 2-year grant, another group received a $10,000 12-month grant, and another group received training and technical assistance but no funding. Nine
FQHCs were selected to participate in qualitative interviews.
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Table 5. Valencea of Constructs of Consolidated Framework for Implementation Research and Level of Funding, Study of Implementing the HPV VACs (Vaccinate Ad-
olescents Against Cancers) Program, May–August 2016
Construct
Received $90,000 Received $10,000
Received Technical Assistance
Only
5 6 7 8 9 3 4 2 1
Intervention characteristic
Evidence of strength 0 0 0 − 0 − 0 0 −
Intervention staff
Knowledge − 0 0 0 0 + 0 + −
Intervention process
Planning: vaccine acquisition and previsit
planning
0 0 + 0 0 + 0 0 +
Executing +/− +/− +/− +/− +/− − +/− +/− +/−
Champions (providers) + 0 + 0 0 0 + + +
External change agents (ACS staff) + + + 0 + 0 + + +
Inner setting
Compatibility +/− 0 − + 0 − 0 0 −
Network and communication − 0 +/− + + − + + +
Implementation climate: staff buy-in − 0 +/− + − 0 +/− + +/−
Relative priority: competing priorities − − − − 0 0 − − −
Leadership engagement 0 0 0 0 + + + + 0
Access to knowledge: training needs − − 0 − 0 − − 0 0
Available resources: level of ACS funding/
cost of program
− 0 0 0 0 − − − −
Outer setting
Patient needs − − +/− − 0 0 + − 0
Policies and mandates: insurance provider
coverage issues
− 0 − 0 0 0 0 − 0
Cosmopolitanism +/− 0 − 0 +/− 0 − − −
Abbreviations: +, positive effect on implementation; −, negative effect on implementation. +/−, mixed effect on implementation, “0”=theme not mentioned in the
interview; ACS, American Cancer Society; EHR, electronic health record; FQHC, federally qualified health center; HPV, human papillomavirus.
a “Valence” refers to the construct’s influence on implementation of the program. We considered valence to be positive (facilitated implementation of the interven-
tion), negative (hindered the implementation), or mixed. Numbers in column headings refer to the FQHC identification number. Thirty FQHC systems implemented
the HPV VACs project. The systems were randomly placed into 3 intervention groups, with 10 systems in each group: one group received a $90,000 2-year grant,
another group received a $10,000 12-month grant, and another group received training and technical assistance but no funding. Nine FQHCs were selected to par-
ticipate in qualitative interviews.
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